Synapsin autoantibodies during pregnancy are associated with fetal abnormalities.
Antineuronal autoantibodies
Growth retardation
Maternofetal autoimmunity
Peptide microarray
Synapsin-I
Transplacental transfer
Journal
Brain, behavior, & immunity - health
ISSN: 2666-3546
Titre abrégé: Brain Behav Immun Health
Pays: United States
ID NLM: 101759062
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
19
08
2023
accepted:
21
08
2023
medline:
11
9
2023
pubmed:
11
9
2023
entrez:
11
9
2023
Statut:
epublish
Résumé
Anti-neuronal autoantibodies can be transplacentally transferred during pregnancy and may cause detrimental effects on fetal development. It is unclear whether autoantibodies against synapsin-I, one of the most abundant synaptic proteins, are associated with developmental abnormalities in humans. We recruited a cohort of 263 pregnant women and detected serum synapsin-I IgG autoantibodies in 13.3% using cell-based assays. Seropositivity was strongly associated with abnormalities of fetal development including structural defects, intrauterine growth retardation, amniotic fluid disorders and neuropsychiatric developmental diseases in previous children (odds ratios of 3-6.5). Autoantibodies reached the fetal circulation and were mainly of IgG1/IgG3 subclasses. They bound to conformational and linear synapsin-I epitopes, five distinct epitopes were identified using peptide microarrays. The findings indicate that synapsin-I autoantibodies may be clinically useful biomarkers or even directly participate in the disease process of neurodevelopmental disorders, thus being potentially amenable to antibody-targeting interventional strategies in the future.
Identifiants
pubmed: 37692096
doi: 10.1016/j.bbih.2023.100678
pii: S2666-3546(23)00092-3
pmc: PMC10483408
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100678Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Ann Neurol. 2014 Jul;76(1):82-94
pubmed: 24853231
Front Immunol. 2023 Jan 19;14:1101087
pubmed: 36742338
Methods Mol Biol. 2023;2578:17-25
pubmed: 36152277
Nat Rev Immunol. 2021 Dec;21(12):798-813
pubmed: 33976421
Cells. 2021 Mar 16;10(3):
pubmed: 33809712
Science. 1989 Sep 29;245(4925):1474-80
pubmed: 2506642
Cell Death Dis. 2019 Nov 14;10(11):864
pubmed: 31727880
Mol Psychiatry. 2016 Dec;21(12):1663-1671
pubmed: 27698429
Brain Behav Immun. 2017 Nov;66:125-134
pubmed: 28733081
Neurol Neuroimmunol Neuroinflamm. 2021 May 27;8(4):
pubmed: 34045306
PLoS One. 2018 Dec 13;13(12):e0208636
pubmed: 30543686
J Med Genet. 2004 Mar;41(3):183-6
pubmed: 14985377
Sci Transl Med. 2014 Nov 19;6(263):263ra158
pubmed: 25411471
Annu Rev Cell Biol. 1990;6:433-60
pubmed: 1980418
Science. 2018 Aug 10;361(6402):604-607
pubmed: 29976799
Nat Rev Mol Cell Biol. 2017 May;18(5):285-298
pubmed: 28225081
J Vis Exp. 2019 Jun 6;(148):
pubmed: 31233034
Sci Transl Med. 2022 Apr 20;14(641):eabe9726
pubmed: 35442708
Trends Neurosci. 2023 Apr;46(4):293-306
pubmed: 36725404
Cell Rep. 2020 Feb 25;30(8):2594-2602.e3
pubmed: 32101738
Nature. 2021 Aug;596(7873):583-589
pubmed: 34265844
Cereb Cortex. 2019 Mar 1;29(3):1230-1243
pubmed: 29425353
Ann Neurol. 2019 Nov;86(5):656-670
pubmed: 31325344
J Neurol Neurosurg Psychiatry. 2017 Sep;88(9):718-721
pubmed: 28572274
Cell Mol Life Sci. 2010 May;67(9):1383-96
pubmed: 20035364
Nature. 1995 Jun 8;375(6531):488-93
pubmed: 7777057
J Neurosci. 2012 Aug 8;32(32):11082-94
pubmed: 22875940
Methods Mol Biol. 2023;2578:143-159
pubmed: 36152285